Anika Therapeutics, Inc. (ANIK)

Every figure this model derived for ANIK, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 5,415,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 64,180,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 99,190,000 AssetsCurrent 2026-06-30
current liabilities 22,147,000 LiabilitiesCurrent 2026-06-30
equity 137,282,000 StockholdersEquity 2026-06-30
ocf 5,977,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 120,654,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 13,147,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up ANIK on one particular measure came for.

RatioValue
cash operating margin11.31
current ratio4.5
current ratio reported4.48
deferred revenue growth163.47
dilution pct-2.6
fcf margin0.47
operating margin-4.24
owner earnings margin-10.43
revenue growth5.33
revenue growth per share8.14
roic-5.53
rule of 401.09
sbc pct revenue10.9

What to be careful about

What this model itself distrusts about ANIK's figures. Written by the derivation as it ran, not added afterwards.